Cargando…

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

PURPOSE: Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node posi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Min-Young, Ku, Bo Mi, Kim, Hae Su, Lee, Ji Yun, Lim, Sung Hee, Sun, Jong-Mu, Lee, Se-Hoon, Park, Keunchil, Oh, Young Lyun, Hong, Mineui, Jeong, Han-Sin, Son, Young-Ik, Baek, Chung-Hwan, Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654158/ https://www.ncbi.nlm.nih.gov/pubmed/28052655 http://dx.doi.org/10.4143/crt.2016.424

Ejemplares similares

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
por: Kim, Hae Su, et al.
Publicado: (2016)

Discrepancies between the ultrasonographic and gross pathological size of papillary thyroid carcinomas
por: Hahn, Soo Yeon, et al.
Publicado: (2016)

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2014)

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
por: Ji, Jun Ho, et al.
Publicado: (2015)

Multifocality and Bilaterality of Papillary Thyroid Microcarcinoma
por: So, Yoon Kyoung, et al.
Publicado: (2015)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer
por: Lee, Myung-Chul, et al.
Publicado: (2019)

Metastatic Lymph Node Ratio of Central Neck Compartment Has Predictive Values for Locoregional Recurrence in Papillary Thyroid Microcarcinoma
por: Choi, Sung Yong, et al.
Publicado: (2016)

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
por: Moon, Seung Hwan, et al.
Publicado: (2015)

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2021)

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
por: Lim, Sung Hee, et al.
Publicado: (2021)

Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer
por: Lee, Jandee, et al.
Publicado: (2015)

Extent of central lymph node dissection for papillary thyroid carcinoma in the isthmus
por: Chang, Young Woo, et al.
Publicado: (2018)

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Koh, Jiae, et al.
Publicado: (2020)

US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population
por: Lim, Hyun Kyung, et al.
Publicado: (2019)

Papillary and medullary thyroid carcinomas coexisting in the same lobe, first suspected based on fine-needle aspiration cytology: a case report
por: Koh, Hyun Hee, et al.
Publicado: (2022)

Impact of Extranodal Extension on Risk Stratification in Papillary Thyroid Carcinoma
por: Kim, Hye In, et al.
Publicado: (2019)

Erratum: US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population
por: Lim, Hyun Kyung, et al.
Publicado: (2020)

Thyroid pathology, a clue to PTEN hamartoma tumor syndrome
por: Lee, Yurimi, et al.
Publicado: (2023)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

A Patient with Primary Squamous Cell Carcinoma of the Thyroid Intermingled with Follicular Thyroid Carcinoma that Remains Alive more than 8 Years after Diagnosis
por: Jung, Tae Sik, et al.
Publicado: (2006)

Columnar Cell Variant of Papillary Thyroid Carcinoma: Ultrasonographic and Clinical Differentiation between the Indolent and Aggressive Types
por: Cho, Jooyeon, et al.
Publicado: (2018)

Predicting Extrathyroidal Extension in Patients With Papillary Thyroid Microcarcinoma According to a BRAF Mutation
por: Lee, Doh Young, et al.
Publicado: (2017)

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences
por: Cho, Minho, et al.
Publicado: (2017)

What is the difference between the tall cell variant and the classic type of papillary thyroid carcinoma on ultrasonography?
por: Kim, Haejung, et al.
Publicado: (2022)

Significance of micrometastases in the calculation of the lymph node ratio for papillary thyroid cancer
por: Chang, Young Woo, et al.
Publicado: (2017)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer
por: Kim, Bu Kyung, et al.
Publicado: (2018)

Papillary Thyroid Carcinoma of a Diffuse Sclerosing Variant: Ultrasonographic Monitoring from a Normal Thyroid Gland to Mass Formation
por: Kim, Hye Seong, et al.
Publicado: (2010)

Co-Occurrence of Hotspot Point Mutation and Novel Deletion Mutation of TERT Promoter in Solid Variant Papillary Thyroid Carcinoma in a Patient with Synchronous Esophageal Cancer
por: Han, Jiheun, et al.
Publicado: (2020)

Is total thyroidectomy with bilateral central neck dissection the only surgery for papillary thyroid carcinoma patients with clinically involved central nodes?
por: Back, Kyorim, et al.
Publicado: (2022)

TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer
por: Myung, Jae Kyung, et al.
Publicado: (2016)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
por: Park, Seung-Jin, et al.
Publicado: (2022)

An increase of CD8(+) T cell infiltration following recurrence is a good prognosticator in HNSCC
por: So, Yoon Kyoung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6v7agevm0kmtofif8bd7vc9nch